Ocugen Inc (OCGN) has disclosed a new risk, in the Accounting & Financial Operations category.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ocugen Inc faces elevated execution risk because it lacks prior experience in marketing, selling, and distributing biotechnology products, making the build‑out of commercial infrastructure costly, time‑consuming, and uncertain in outcome. Its reliance on attracting and retaining specialized talent, while managing operational growth and higher public‑company compliance burdens as a smaller reporting company, further increases the likelihood of delays, control weaknesses, reputational damage, or product liability and cybersecurity events that could materially impact shareholder value.
The average OCGN stock price target is $7.67, implying 340.80% upside potential.
To learn more about Ocugen Inc’s risk factors, click here.